Michael Edward Burczynski

US Patent:

7643943, Jan 5, 2010

Filed:

Mar 5, 2004

Appl. No.:

10/793032

Inventors:

Michael E. Burczynski - Collegeville PA, US
Joseph Boni - Wayne PA, US
Andrew J. Dorner - Lexington MA, US
Natalie C. Twine - Goofstown NH, US
Jennifer Stover - Topsfield MA, US
William L. Trepicchio - Andover MA, US
Virginia Fitzpatrick - Norristown PA, US
Fred Immermann - Suffern NY, US

Assignee:

Wyeth LLC - Madison NJ

International Classification:

G01N 33/48

US Classification:

702 19

Abstract:

Methods, systems and equipment useful for monitoring in vivo activities of CCI-779 or other drugs. Numerous drug activity genes can be identified by the present invention. The expression profiles of these genes in peripheral blood mononuclear cells are modulatable by CCI-779 or other drugs. Therefore, these genes can be used as surrogate markers for detecting or monitoring drug activities in vivo.

US Patent:

20040175743, Sep 9, 2004

Filed:

Feb 11, 2004

Appl. No.:

10/775169

Inventors:

Michael Burczynski - Swampscott MA, US
Natalie Twine - Goffstown NH, US
Andrew Dorner - Lexington MA, US
William Trepicchio - Andover MA, US

International Classification:

C12Q001/68
G01N033/567

US Classification:

435/006000, 435/007210

Abstract:

Methods, systems and equipment useful for monitoring in vivo activities of CCI-779 or other drugs. Numerous drug activity genes can be identified by the present invention. The expression profiles of these genes in peripheral blood mononuclear cells can be modulated by CCI-779 or other drugs. Therefore, these genes can be used as surrogate markers for monitoring drug activities in vivo.

US Patent:

20050202451, Sep 15, 2005

Filed:

Apr 29, 2004

Appl. No.:

10/834114

Inventors:

Michael Burczynski - Swampscott MA, US
Andrew Dorner - Lexington MA, US
Natalie Twine - Goffstown NH, US
William Trepicchio - Andover MA, US
Jennifer Stover - Topsfield MA, US

International Classification:

C12Q001/68

US Classification:

435006000

Abstract:

Methods, systems and equipment for diagnosing or monitoring the progression or treatment of AML or MDS. This invention identifies a plurality of AML or MDS disease genes which are differentially expressed in bone marrow cells of AML or MDS patients as compared to disease-free humans. These AML or MDS disease genes can be used as molecular markers for detecting the presence or absence of AML or MDS. These genes can also be used for the early identification of MDS patients who eventually progress to AML.

US Patent:

20060134671, Jun 22, 2006

Filed:

Nov 22, 2005

Appl. No.:

11/285502

Inventors:

Michael Burczynski - Collegeville PA, US
Andrew Dorner - Lexington MA, US
Natalie Twine - Goffstown NH, US
William Trepicchio - Andover MA, US
Donna Slonim - North Andover MA, US
Andrew Strahs - Maynard MA, US
Frederick Immermann - Suffern NY, US

Assignee:

Wyeth - Madison NJ

International Classification:

C12Q 1/68
G06F 19/00

US Classification:

435006000, 702020000

Abstract:

The present invention provides methods, systems and equipment for the prognosis and treatment of renal cell carcinoma (RCC) or other solid tumors. Genes prognostic of clinical outcomes of a solid tumor can be identified according to the present invention. The expression profiles of these genes in peripheral blood mononuclear cells (PBMCs) of patients who have the solid tumor are correlated with clinical outcome of these patients. Examples of RCC prognosis genes are illustrated in Tables 2 and 3. These genes can be used as surrogate markers for predicting clinical outcome of an RCC patient of interest. These genes can also be used for the selection of a favorable treatment for an RCC patient of interest.

US Patent:

20060194211, Aug 31, 2006

Filed:

Apr 29, 2004

Appl. No.:

10/834268

Inventors:

Michael Burczynski - Swampscott MA, US
Natalie Twine - Goffstown NH, US
William Trepicchio - Andover MA, US
Andrew Strahs - Maynard MA, US
Fred Immermann - Suffern NY, US
Donna Slonim - North Andover MA, US
Andrew Dorner - Lexington MA, US

International Classification:

C12Q 1/68
G01N 33/574

US Classification:

435006000, 435007230

Abstract:

Solid tumor prognosis genes, and methods, systems and equipment of using these genes for the prognosis and treatment of solid tumors. Prognosis genes for a solid tumor can be identified by the present invention. The expression profiles of these genes in peripheral blood mononuclear cells (PBMCs) are correlated with clinical outcome of the solid tumor. The prognosis genes of the present invention can be used as surrogate markers for predicting clinical outcome of a solid tumor in a patient of interest. These genes can also be used to select a treatment which has a favorable prognosis for the solid tumor of the patient of interest.

US Patent:

20070020660, Jan 25, 2007

Filed:

Jun 6, 2006

Appl. No.:

11/448611

Inventors:

Michael Burczynski - Collegeville PA, US
Ron Peterson - North Chelmsford MA, US
Natalie Twine - Goffstown NH, US
Andrew Strahs - Maynard MA, US
Frederick Immermann - Suffern NY, US
Ullrich Schwertschlag - Beverly Farms MA, US
Monette Cotreau - Acton MA, US
Andrew Dorner - Lexington MA, US

International Classification:

C12Q 1/68
C12P 19/34

US Classification:

435006000, 435091200

Abstract:

The present invention is directed to the identification of PBMC- and IBD-associated biomarkers that may be used to diagnose inflammatory bowel disease, and optionally, distinguish between PBMCs isolated from a patient with Crohn's disease and PBMCs isolated from a patient with ulcerative colitis. The present invention is further directed to methods of screening, including high throughput methods of screening, for regulatory agents capable of regulating the activity of PBMC- and IBD-associated biomarkers. Provided are compositions of PBMC- and IBD-associated biomarkers, including regulatory agents of at least one PBMC- and IBD-associated biomarker for methods of diagnosis, prognosis, therapeutic intervention and prevention of an inflammatory bowel disease, e.g., Crohn's disease and ulcerative colitis. Moreover, the present invention is also directed to methods that can be used to assess the efficacy of test compounds and therapies in the treatment inflammatory bowel disease, i.e., Crohn's disease or ulcerative colitis.

US Patent:

20070198198, Aug 23, 2007

Filed:

Apr 23, 2007

Appl. No.:

11/789104

Inventors:

Michael Burczynski - Swampscott MA, US
Andrew Dorner - Lexington MA, US
Natalie Twine - Goffstown NH, US
William Trepicchio - Andover MA, US
Jennifer Stover - Topsfield MA, US

Assignee:

Wyeth - Madison NJ

International Classification:

C12Q 1/68
G06F 19/00

US Classification:

702020000, 435006000

Abstract:

Methods, systems and equipment for diagnosing or monitoring the progression or treatment of AML or MDS. This invention identifies a plurality of AML or MDS disease genes which are differentially expressed in bone marrow cells of AML or MDS patients as compared to disease-free humans. These AML or MDS disease genes can be used as molecular markers for detecting the presence or absence of AML or MDS. These genes can also be used for the early identification of MDS patients who eventually progress to AML.

US Patent:

20080032299, Feb 7, 2008

Filed:

Mar 8, 2007

Appl. No.:

11/715606

Inventors:

Michael Burczynski - Swampscott MA, US
Natalie Twine - Goffstown NH, US
William Trepicchio - Andover MA, US
Andrew Strahs - Maynard MA, US
Fred Immermann - Suffern NY, US
Donna Slonim - North Andover MA, US
Andrew Dorner - Lexington MA, US

Assignee:

Wyeth - Madison NJ

International Classification:

C12Q 1/68
C40B 40/08
C40B 40/10
G06G 7/48

US Classification:

435006000, 506017000, 506018000, 703011000

Abstract:

Solid tumor prognosis genes, and methods, systems and equipment of using these genes for the prognosis and treatment of solid tumors. Prognosis genes for a solid tumor can be identified by the present invention. The expression profiles of these genes in peripheral blood mononuclear cells (PBMCs) are correlated with clinical outcome of the solid tumor. The prognosis genes of the present invention can be used as surrogate markers for predicting clinical outcome of a solid tumor in a patient of interest. These genes can also be used to select a treatment which has a favorable prognosis for the solid tumor of the patient of interest.

Author:

Michael E. Burczynski

ISBN #:

0849313341